CSE:SONA - Post Discussion
Post by
Betteryear2 on Mar 25, 2024 3:48pm
Sona Nanotech Updates on Dalhousie Efficacy Study
Halifax, Nova Scotia--(Newsfile Corp. - March 25, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). An update received by the Company indicates that all tumors treated within the Study to date with a single Targeted Hyperthermia Therapy ("THT") treatment shrunk within the first 24 hours, with an average reduction in size of 80% compared to matched controls. Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results (newsfilecorp.com)
Be the first to comment on this post